Dataset Information

Human urine proteome in overactive bladder syndorme

ABSTRACT: The aim of this study is analysis of urinary proteomic pattern in healthy people and patients suffering from OAB symptoms by means of mass spectrophotometry. Establishing characteristic protein profiles, qualitative and quantitative, for OAB will help to define specific protein marker and will allow to develop new investigative protocol enabling to discover at what stage of post-genetic changes urothelium cells change their proteomic profile causing OAB symptoms. Patients will be divided into two groups: group A – OAB patients and group B – control group, without any urinary tract symptoms. All participants will be questionnaired with appropriate tools evaluating quality of life of patients with lower urinary tract symptoms and bladder diary. Urine samples will be taken twice with 7 day gap and then prepared for further evaluation with mass spectrophotometry. Mass spectrophotometry will be performed for all labeled samples with QExactive spectrophotometer. In order to provide maximal credibility and reliability of acquired data each sample will be managed in triplicate. Those result will be analyzed with specific statistical methods and final results will be correlated between the groups. In long-term perspective results of this project will help to understand the underlying pathomechanisms of overactive blabber syndrome. In future those results will be applied for further research in OAB sufferers allowing for precise and objective diagnosis and prognosis. In our opinion it will also serve as a tool for estimations of treatment efficacy of new therapeutic methods. In consequence the project will allow us to create a unique toolkit, combining spectrophotometry, urinary proteomic pattern differences and quality of life correlated with OAB symptoms severity. It will enable to develop new perspectives for overactive bladder pathophysiology research and new therapeutic strategies.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Urine

DISEASE(S): Urinary Frequency,Urgency Of Urination

SUBMITTER: Konrad Futyma

LAB HEAD: Michał Dadlez

PROVIDER: PXD017799 | Pride | 2020-05-12

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	80502566nowa_ExpOABK1_hpH_01.raw	Raw
	80502566nowa_ExpOABK1_hpH_02.raw	Raw
	80502566nowa_ExpOABK1_hpH_03.raw	Raw
	80502566nowa_ExpOABK1_hpH_04.raw	Raw
	80502566nowa_ExpOABK1_hpH_06.raw	Raw

Items per page:

1 - 5 of 47

Publications

Urine Proteomic Study in OAB Patients-Preliminary Report.

Futyma Konrad K Nowakowski Łukasz Ł Ziętek-Strobl Alicja A Kamińska Aleksandra A Taoussi Nadia N Rechberger Tomasz T

Journal of clinical medicine 20200508 5

Overactive bladder (OAB) is defined by International Urogynecological Association (IUGA)/ International Continence Society (ICS) as urinary urgency, usually accompanied by frequency and nocturia, with or without urgency urinary incontinence, in the absence of urinary tract infection (UTI) or other obvious pathology. The pathophysiology of OAB is not well understood, however a number of different proteins and cytokines including vascular cell adhesion molecule-1 (VCAM-1) were found to be importan ...[more]

PMID: 32397227

Similar Datasets

Project description:Cystinuria is the most frequent monogenic cause of renal calculi. We previously described a urinary inflammatory signature in 8 cystinuric patients through quantitative proteomic analysis. Our data suggested an association of abnormal renal function and an inflammatory protein profile. The objectives of the present study were to investigate: i) the urinary proteomic profile in cystinuric patients without chronic kidney disease (CKD), and in a control group of healthy volunteers; ii) the potential effect of urine alkalinization on the urinary proteomic profile in cystinuric patients as this is the cornerstone of the preventive medical treatment. Urinary inflammatory profile was evaluated at baseline in the control group and in cystinuric patients not yet treated or for whom the alkalizing treatment or the cysteine- binding thiols have been discontinuated for at least 3 months and with an eGFR (using the CKD-EPI formula) greater than 60 ml/min/1.73m2 (so without CKD G3-G5). In cystinuric patients, change from baseline urinary inflammatory profile was evaluated after 3 months of alkalizing treatment. Urine proteome was analyzed by Nano- liquid chromatography coupled to high resolution mass spectrometry. Twenty-one cystinuric patients (12 men, median age [IQR] 30.0 years [25.0 – 44.0]), and 7 healthy volunteers (2 men, median age 43.1 years [31.0 – 53.9]) were included. Median eGFR in these two groups was 95 ml/min/1.73m2 [87.5 – 111.5] and 116 ml/min/1.73m2 [91.0 – 120.0] respectively (p=0.38). Healthy volunteers had no inflammatory signature. The inflammatory signature was present in the cystinuric patients at different degrees. A hierarchical clustering of the cystinuric patients according to the intensity of the profile of core inflammation signature (11 proteins) was performed. The signature could clearly separate 5 cystinuric patients with a high inflammation from other cystinuric patients and healthy volunteers. The alkalizing treatment was associated with a decrease in the intensity of the urinary inflammatory profile in all 5 cystinuric patients compared to the initial high level of urinary inflammation. A panel of 11 proteins was found as elevated in some cystinuric patients without CKD G3- G5 and could work as an early inflammatory signature. The alkalizing treatment was associated with a reduction of this urinary inflammation signature, suggesting that this panel of proteins could also be a new tool to monitor the treatment of cystinuric patient.